Aclaris Therapeutics, Inc.
ACRS
$4.88
-$0.07-1.41%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 8.37M | 7.83M | 15.74M | 16.79M | 17.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.37M | 7.83M | 15.74M | 16.79M | 17.78M |
| Cost of Revenue | 64.27M | 59.93M | 60.20M | 53.09M | 50.46M |
| Gross Profit | -55.91M | -52.10M | -44.46M | -36.30M | -32.68M |
| SG&A Expenses | 22.58M | 21.97M | 21.35M | 22.13M | 21.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 86.85M | 81.90M | 81.55M | 75.22M | 71.96M |
| Operating Income | -78.48M | -74.08M | -65.81M | -58.43M | -54.18M |
| Income Before Tax | -69.66M | -64.92M | -141.68M | -134.65M | -130.21M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.66 | -64.92 | -141.68 | -134.65 | -130.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.66M | -64.92M | -141.68M | -134.65M | -130.21M |
| EBIT | -78.48M | -74.08M | -65.81M | -58.43M | -54.18M |
| EBITDA | -78.43M | -74.00M | -65.70M | -58.26M | -53.99M |
| EPS Basic | -0.56 | -0.53 | -1.38 | -1.37 | -1.40 |
| Normalized Basic EPS | -0.34 | -0.32 | -0.29 | -0.28 | -0.30 |
| EPS Diluted | -0.56 | -0.53 | -1.38 | -1.37 | -1.40 |
| Normalized Diluted EPS | -0.34 | -0.32 | -0.29 | -0.28 | -0.30 |
| Average Basic Shares Outstanding | 496.68M | 490.26M | 462.90M | 411.66M | 360.37M |
| Average Diluted Shares Outstanding | 496.68M | 490.26M | 462.90M | 411.66M | 360.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |